Sporadic CDKN2 (MTS1/p16(ink4)) gene alterations in human ovarian tumours

British Journal of Cancer

Volumn 74, Issue 7, 1996, Pages 1069-1073

  Schuyer, M ^a   Van Staveren, I L ^a   Klijn, J G M ^a   V D Burg, M E L ^a   Stoter, G ^a   Henzen Logmans, S C ^a   Foekens, J A ^a   Berns, E M J J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

CDKN2; MTS1; Mutation; Ovarian cancer; P16(ink4); TP53

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLINE; PROTEIN P21;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CHROMOSOME 9P; CLINICAL ARTICLE; CONTROLLED STUDY; EXON; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION; GENE MAPPING; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; OVARY ADENOCARCINOMA; OVARY CANCER; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; STOP CODON;

EID: 0029763773     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.491     Document Type: Article

References (35)

1. BERNS EMJJ, KLIJN JGM, SMID M, VAN STAVEREN IL, GRUIS NA AND FOEKENS JA. (1995). Infrequent CDKN2 (MTS1/p16) gene alterations in human primary breast cancer. Br. J. Cancer, 72, 964-967.
2. CAIRNS P, MAO L, MERLO A, LEE DJ, SCHWAB D, EBY Y, TOKINO K, VAN DER RIET P, BLAUGRUND JE AND SIDRANSKY D. (1994). Rates of p16 (MTS-1) mutations in primary tumors with 9p loss. Science, 265, 415-416.
3. CALDAS C, HAHN SA, DA COSTA LT, REDSTON MS, SCHUTTE M, SEYMOUR AB, WEINSTEIN CL, HRUBAN RH, YEO CJ AND KERN SE. (1994). Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet., 8, 27-32.
4. CAMBELL IG, BEYNON G, DAVIS M AND ENGLEFIELD P. (1995). LOH and mutation analysis of CDKN2 in primary human ovarian cancers. Int. J. Cancer, 63, 222-225.
5. CHENEVIX-TRENCH G, KERR J, FRIEDLANDER M, HURST T, SANDERSON B, COGLAN M, WARD B, LEARY J AND KHOO SK. (1994). Homozygous deletions on the short arm of chromosome 9 in ovarian adenocarcinoma cell lines and loss of heterozygosity in sporadic tumors. Am. J. Hum. Genet., 55, 143-149.
6. CHENG JQ, JHANWAR SC, KLEIN WM, BELL DW, LEE W-C, ALTOMARE DA, NOBORI T, OLOPADE OI, BUCKLER AJ AND TESTA JR. (1994). p16 alterations and deletion mapping of 9p21-22 in malignant mesothelioma. Cancer Res., 54, 5547-5551.
7. EL-DEIRY WS, TOKINO T, VELCULESCU VE, LEVY DB, PARSONS R, TRENT JM, LIN D, MERCER WE, KINZLER KW AND VOGELSTEIN B. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817-825.
8. EL-DEIRY WS, HARPER JW, O'CONNOR PM ET AL. (1994). WAF1/ CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res., 54, 1169-1174.
9. GREENBLATT MS, BENNETT WP, HOLLSTEIN M AND HARRIS CC. (1994). Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54, 4855-4878.
10. HARPER JW, ADAMI GR, WEI N, KEYOMARSI K AND ELLEDGE SJ. (1993). The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75, 805-816.
11. HARTWELL LH AND KASTAN MB. (1994). Cell cycle control and cancer. Science, 266, 1821-1828.
12. HAYASHI K AND YANDELL DW. (1993). How sensitive is PCR-SSCP? Hum. Mutat., 2, 338-346.
13. HAYASHI N, SUGIMOTO Y, TSUCHIYA E, OGAWA M AND NAKAMURA Y. (1994). Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK4I (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem. Biophys. Res. Commun., 202, 1426-1430.
14. HERMAN JG, MERLO A, MAO L, LAPIDUS RG, ISSA JPJ, DAVIDSON NE, SIDRANSKY D AND BAYLIN SB. (1995). Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res., 55, 4525-4530.
15. HUNTER T AND PINES J. (1994). Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell, 79, 573-582.
16. HUSSUSSIAN CJ, STRUEWING JD, GOLSTEIN AM, HIGGINGS PAT, ALLY DS, SHEAHAN MD, CLARK WH, TUCKER MA AND DRACOPOLI NC. (1994). Germline p16 mutations in familial melanoma. Nature Genet., 8, 15-21.
17. KAMB A, GRUIS NA, WEAVER-FELDHAUS J, LIU Q, HARSHMAN K, TAVTIGIAN SV, STOCKERT E, DAY III RS, JOHNSON BE AND SKOLNICK MH. (1994). A cell cycle regulator potentially involved in genesis of many tumor types. Science, 264, 436-440.
18. LYDIATT WM, MURTY VVVS, DAVIDSON BJ, XU L, DYOMINA K, SACKS PG, SHANTZ SP AND CHAGANTI RSK. (1995). Homozygous deletions and loss of expression of the CDKN2 gene occur frequently in head and neck squamous cell carcinoma cell lines but infrequently in primary tumors. Genes, Chrom, Cancer, 13, 94-98.
19. MERLO A, HERMAN JG, MAO L, LEE DJ, GABRIELSON E, BURGER PC, BAYLIN SB AND SIDRANSKY D. (1995). Nature Med., 1, 686-692.
20. MORI T, MIURA K, AOKI T, NISHIHIRA T, MORI S AND NAKAMURA Y. (1994). Frequent somatic mutation of the MTSI/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res., 54, 3396-3397.
21. NOBORI T, MIURA K, WU DJ, LOIS A, TAKABAYASHI K AND CARSON DA. (1994). Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature, 368, 753-756.
22. INK4 in human cancer. Proc. Natl Acad. Sci. USA, 91, 11045-11049.
23. ORITA M, SUZUKI Y, SEKIYA T AND HAYASHI K. (1989). Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics, 5, 874-879.
24. SAMBROOK J, FRITSCH EF AND MANIATIS T. (1989). Molecular Cloning: A Laboratory Manual. 2nd edition. Cold Spring Harbor Laboratory Press: New York.
25. SCHMIDT EE, ICHIMURA K, REIFENBERGER G AND COLLINS VP. (1994). CDKN2 (p16/MTSI) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res., 54, 6321-6324.
26. SCHULTZ DC, VANDERVEER L, BUETOW KH, BOENTE MP, OZOLS RF, HAMILON TC AND GODWIN AK. (1995). Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Cancer Res., 55, 2150-2157.
27. SERRANO M, HANNON GJ AND BEACH D. (1993). A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/ CDK4. Nature, 366, 704-707.
28. SHELLING AN, COOKE IE AND GANESAN TS. (1995). The genetic analysis of ovarian cancer. Br. J. Cancer, 72, 521-527.
29. 1 cyclins. Cell, 73, 1059-1065.
30. SPRUCK CH, GONZALEZ-ZULUETA MG, SHIBATA A, SIMONEAU AR, LIN M-F, GONZALES F, TSAI YC AND JONES PA. (1994). p16 gene in uncultured tumours. Nature, 370, 183-184.
31. WEITZEL JN, PATEL J, SMITH DM, GOODMAN A, SAFAII H AND BALL HG. (1994). Molecular genetic changes associated with ovarian cancer. Gynecol. Oncol., 55, 245-252.
32. WORLD HEALTH ORGANIZATION. (1979). WHO Handbook for Reporting Results of Cancer Treatments. World Health Organization Offset Publication no. 48. WHO: Geneva.
33. XIONG Y, HANNON GJ, ZHANG H, CASSO D, KOBAYASHI R AND BEACH D. (1993). p21 is a universal inhibitor of cyclin kinases. Nature, 366, 701-704.
34. ink4) in human breast carcinomas. Cancer Res., 54, 5262-5264.
35. ZHANG S-Y, KLEIN-SZANTO AJP, SAUTER ER, SHAFARENKO M, MITSUNAGA S, NOBORI T, CARSON DA, RIDGE JA AND GOODROW TL. (1994). Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res., 54, 5050-5053.